

CDK9-IN-2

Catalog No: tcsc1252



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

1263369-28-3

Formula:

$C_{23}H_{25}ClFN_5$

Pathway:

Cell Cycle/DNA Damage

Target:

CDK

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

425.93


Product Description

CDK9-IN-2 is a special cyclin-dependent kinase 9 (**CDK9**) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an **IC₅₀**

of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.

IC50 & Target: IC50: 5 nM (CDK9, in H929 multiple myeloma cell line), 7 nM (CDK9, in A2058 skin cell line)^[1]

In Vitro: CDK9-IN-2 (200 nM) reduces the expression of MEPCE indicating that MEPCE is a pharmacodynamic (PD) marker for any CDK9 inhibitor. The expression of MCL1 protein is reduced 2 hours after treatment and is further reduced after 16 hour exposure to CDK9-IN-2 (500 nM)^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!